PLEASANTON, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), announced updated clinical trial ...
ProSomnus, Inc. (NASDAQ: OSA), a provider of an alternative treatment for Obstructive Sleep Apnea, released new clinical trial data showing that the First Line Obstructive Sleep Apnea Treatment study ...
Medical devices are gathering more and more data from their users, whether it’s their heart rates, sleep patterns or the number of steps taken in a day. Insurers and medical device makers say such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback